Home > Healthcare > Pharmaceuticals > Finished Drug Form > Liver Cancer Drugs Market
Liver Cancer Drugs Market Size
- Report ID: GMI9707
- Published Date: May 2024
- Report Format: PDF
Liver Cancer Drugs Market Size
Liver Cancer Drugs Market was valued at USD 2.9 billion in 2023 and is estimated to grow at 11.8% CAGR from 2024 to 2032, due to the rising incidence of liver cancer, awareness for early detection, growing research capabilities for potential treatment. The global burden of liver cancer is driven by factors such as increasing rates of hepatitis infections, alcohol consumption and obesity many others. According to the National Center for Biotechnology Information (NCBI), liver cancer is a major global health concern, projected to affect over 1 million people by 2025. Therefore, the growing incidence of liver cancer along with advancement in liver cancer diagnostics anticipate the market growth in the coming years.
Liver cancer drugs are pharmaceutical treatments specifically designed to combat liver cancer, a malignant condition affecting the liver. These drugs include various classes such as targeted therapies, immunotherapies, and chemotherapy agents. The development and use of these drugs aim to inhibit tumor growth, reducing the symptoms, and improving survival rates, of liver cancer patients.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Liver Cancer Drugs Market Size in 2023: | USD 2.9 Billion |
| Forecast Period: | 2024 - 2032 |
| Forecast Period 2024 - 2032 CAGR: | 11.8% |
| 2032 Value Projection: | USD 7.6 Billion |
| Historical Data for: | 2021 - 2023 |
| No. of Pages: | 160 |
| Tables, Charts & Figures: | 272 |
| Segments covered: | Type, Drug Class, Route of Administration, Medication Type, Gender, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Liver Cancer Drugs Market Scope
